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 50 
Abstract   51 
Type 2 diabetes (T2D) is a prevalent risk factor for tuberculosis (TB), but most studies on TB-T2D have 52 
focused on TB patients, been limited to one community, and shown a variable impact of T2D on TB risk 53 
or treatment outcomes. We conducted a cross-sectional assessment of sociodemographic and metabolic 54 
factors in adult TB contacts with T2D (versus no T2D), from the Texas-Mexico border to study Hispanics, 55 
and in Cape Town to study South African Coloured ethnicities. The prevalence of T2D was 30.2% in 56 
Texas-Mexico and 17.4% in South Africa, with new diagnosis in 34.4% and 43.9%, respectively. Contacts 57 
with T2D differed between ethnicities, with higher smoking, hormonal contraceptive use and cholesterol 58 
levels in South Africa, and higher obesity in Texas-Mexico (p <0.05). PCA analysis revealed striking 59 
differences between ethnicities in the relationships between factors defining T2D and dyslipidemias. 60 
Our findings suggest that screening for new T2D in adult TB contacts is effective to identify new T2D 61 
patients at risk for TB. Furthermore, studies aimed at predicting individual TB risk in T2D patients, should 62 
take into account the heterogeneity in dyslipidemias that are likely to modify the estimates of TB risk or 63 
adverse treatment outcomes that are generally attributed to T2D alone. 64 
 65 
Keywords: tuberculosis; diabetes; ethnic; metabolism; cardiovascular; cholesterol 66 
 67 
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1. Introduction 69 
The growing pandemic of type 2 diabetes mellitus (T2D) is a challenge to tuberculosis (TB) control. 70 
Individuals with T2D have a 3-fold increased risk of TB, particularly if they have poor glucose control or 71 
additional T2D complications [1-3]. However, the increased TB risk in patients with T2D varies widely 72 
between studies, regions and populations, with risk estimates ranging from 0.99 to 7.83. Likewise, at the 73 
population level, the contribution of T2D to TB is generally between 10-20%, with substantial variation 74 
depending on the local epidemiology [1, 4]. 75 
 76 
Once a patient with T2D develops TB, they appear to be more likely to have delays in the conversion of 77 
sputum smears from positive to negative during TB treatment, to fail treatment, or to relapse [5-7].  78 
However, not all studies report these associations between adverse treatment outcomes and T2D, and if 79 
so, there are variations in their magnitude. This heterogeneity illustrates the complexity of studying T2D 80 
as a risk factor for TB and may be explained by variability in study populations with respect to T2D (e.g., 81 
glucose control, medications, co-morbidities), sociodemographics and access to healthcare, or variations 82 
in study designs [8]. Few interactions between T2D and other host characteristics have been described, 83 
as suggested for T2D plus smoking or micro and macro-vascular diseases [9-12]. While more studies of 84 
this nature are needed among TB patients, there are even fewer studies in TB contacts with T2D. This is 85 
a particularly important population for TB control given that TB contacts have one of the highest risks 86 
for TB progression (5% in the first year of exposure to a pulmonary TB patient), and those with T2D will 87 
magnify this risk by 3-fold [3, 13].  88 
 89 
The goal of the present study was to compare sociodemographic and metabolic risk factors for TB 90 
among TB contacts with T2D from two distant communities with differing ethnicities and cultures. We 91 
enrolled South African Coloureds in the Western Cape of South Africa (TB 625/100,000/year; HIV <6%; 92 
T2D range 8-28%), and Hispanics in south Texas (T2D 19%; HIV 0.14/100,000; TB 10/100,000/year) and 93 
northern Mexico (T2D 15%; TB 32/100,000/year) [1, 14-16]. Our study revealed two major findings: A 94 
high frequency of new T2D among the TB contacts from both regions, and striking differences between 95 
ethnicities in metabolic and sociodemographic characteristics that are likely to modify the risk of TB 96 
conferred by T2D.  97 
 98 
2. Methods 99 
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Participants were enrolled at clinics in south Texas (Hidalgo and Cameron County Health Departments), 100 
northern Mexico (Centro Regional de Tuberculosis in Reynosa; ‘Texas-Mexico’ in this study) and South 101 
Africa (public healthcare clinics around the Tygerberg Academic Hospital in Cape Town; ‘South Africa’ in 102 
this study). Close contacts were defined as sharing at least 5 hours per week in a house or closed space 103 
with a confirmed pulmonary TB source. Active TB was ruled out based on lack of signs and symptoms 104 
compatible with TB, and by normal chest x-ray (routine in Texas and South Africa, and upon physician 105 
request in Mexico).  At both study sites, we enriched for T2D by initially enrolling contacts 30-65 years 106 
old and eventually elevating the lower age to 35 years. In South Africa, all eligible participants were 107 
screened for T2D by HbA1c and FBG to determine accurate prevalence data. From those, all participants 108 
with an HbA1c ≥ 6.5 % were fully enrolled into the study and blood samples were collected for the 109 
downstream analysis, whereas only randomly selected participants with HbA1c ≤ 6.5% were enrolled on 110 
the basis of one normoglycemic participant per participant with hyperglycemia. Exclusion criteria 111 
included a body-mass index (BMI) < 18.5, HIV infection, type 1 diabetes, cancer and recent infections. 112 
The study was approved by the institutional review boards of the participating institutions and 113 
participants signed a free informed consent.   114 
 115 
Diabetes classification was based on hyperglycemia (fasting plasma glucose ≥126 mg/dL), HbA1c ≥ 6.5% 116 
or self-report, and pre-T2D as HbA1c 5.7-6.49% [17]. Macro- and micro-vascular pathologies were self-117 
reported. The frequency of alcohol consumption and the average number of alcoholic drinks consumed 118 
in a typical day were established using validated questions described previously [18]. Alcohol excess was 119 
defined as drinking ≥7 drinks/episode at least weekly or binge drinking (≥10 drinks/episode at least 120 
twice a month), and alcohol abuse was defined as consumption of more than 7 drinks per day on a daily 121 
basis. Drug use was based on self-reported use of injectable or non-injectable illicit drugs at least twice 122 
per week. Latent TB infection (LTBI) was based on QuantiFERON-Gold In-Tube (Qiagen). Plasma LDL 123 
cholesterol (LDL-c) was measured in South Africa, and calculated for Texas [Total cholesterol - HDL-c - 124 
(Triglycerides *0.20)] [19]. Insulin resistance was based on the homeostasis model assessment (HOMA-125 
IR) [fasting plasma glucose (mM)*fasting serum insulin (mU/L)/22.5] on participants who did not use 126 
insulin [20]. 127 
 128 
Data were entered into RedCap (Vanderbilt University) and exported into SAS (v9.4 Cary, NC) or SPSS 129 
(v23.0 Armonk, NY) for analysis.  Chi-square or Fisher’s exact tests were used to compare categorical 130 
variables and two-sample test proportions to identify differences between study sites. Mixed-model 131 
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designs for analysis of covariance (ANCOVA) were performed and the F statistic transformed to Cohen-d. 132 
A Latent Factor analysis using Principal Components approach (PCA) was done and Varimax axes 133 
rotation was used for eigen vector interpretation. P values were considered significant if ≤ 0.05, and 134 
marginally significant if <0.1. 
 
 135 
 136 
3. Results 137 
3.1 Characteristics of all TB contacts  138 
We enrolled 95 contacts (after screening 247 for T2D) in South Africa, and 106 in Texas-Mexico (46 in 139 
Mexico and 60 in Texas; all those screened were enrolled). The contacts from both sites were 140 
predominantly females, but differed in several aspects: In Texas-Mexico nearly all (98%) were Hispanic 141 
whites and in South Africa all were South African Coloureds, a mixed ancestry population with Khoisan, 142 
Bantu, European and Asian roots. The Texas-Mexico contacts were younger, more educated and obese 143 
(Table 1 and Fig 1A; p<0.001), while those in South Africa were more likely to smoke and there was a 144 
higher proportion of females reporting contraceptive use (p<0.003). Their medical history differed 145 
between study sites in various ways (Table S1). Those in Texas-Mexico were more likely to have a family 146 
history of T2D (p=0.005), take anti-inflammatory medications (p=0.002) or vitamin supplements 147 
(p=0.001) and were less likely to have previous TB or current LTBI (p <0.001).  148 
 149 
3.2 Prevalence of pre-T2D and T2D  150 
In Texas-Mexico we identified 32 contacts with T2D (30.2%) and 26 with pre-T2D (24.5%; 54.7% with 151 
both). In South Africa, we screened for elevated HbA1c in 247 TB contacts and identified 43 with T2D 152 
(17.4%) and 56 with pre-T2D (22.7%; 40.1% with both). Thus, the prevalence of T2D and pre-T2D was 153 
high in both communities, and significantly higher in Texas-Mexico (p=0.007). Among those with T2D, 154 
34.4% were newly diagnosed in Texas-Mexico and 43.9% in South Africa. In South Africa, we invited all 155 
of the pre-screened contacts with T2D and a similar number of no T2D controls (without taking into 156 
account pre-T2D status) for full enrollment [total n=95; 41 (43.2%) with T2D and 21 (22.1%) with pre-157 
T2D].   158 
 159 
3.3 Sociodemographic and medical history by T2D status and study site  160 
Analysis was done by T2D status (2 categories) and also including pre-T2D (3 categories), but the latter 161 
results are only described when there were detectable differences in the pre-T2D group. The contacts 162 
with T2D (versus no T2D) were older at both study sites, and in South Africa they were also more likely 163 
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to be obese and female (Table 1). Contacts with T2D (versus no T2D) from both study sites were more 164 
likely to have a family history of T2D, and a higher frequency of macro or micro-vascular complications. 165 
Between study sites, the T2D contacts from Texas-Mexico (versus South Africa) had a higher level of 166 
education, were more obese and had higher waist-hip ratios, but reported less smoking (p<0.001) or 167 
hormonal contraceptive use (Table 1; p=0.003). The T2D patients from Texas-Mexico (versus South 168 
Africa) were more likely to take anti-inflammatory medications (p=0.006) and vitamin supplements 169 
(p=0.017), but they were less likely to have a previous history of TB (p=0.013) or current LTBI (p=0.008; 170 
Table S1).   171 
 172 
3.4 Glucose metabolism-related characteristics by T2D status and study site 173 
There were three differences between the T2D contacts from both study sites with respect to glucose 174 
metabolism. First, there was a trend for a higher proportion of elevated HbA1c in the presence of 175 
otherwise normal fasting plasma glucose in South Africa (34.1%) versus Texas-Mexico (18.2%); Figure 2; 176 
p = 0.128). The second difference was related to insulin resistance. As expected, insulin levels and insulin 177 
resistance (HOMA-IR) were higher among the T2D contacts (Table 2), but insulin resistance was also 178 
higher in the no T2D contacts from Texas-Mexico versus South Africa (p=0.017). We hypothesize this 179 
difference was related to the higher BMI and triglycerides in Texas-Mexico (Tables 1, 2; Figs 1,4), given 180 
that insulin resistance is associated with obesity and can be driven by free fatty acids, which are 181 
triglyceride metabolites [21]. Thus, we evaluated the relationships between BMI or triglycerides on 182 
HOMA-IR. As expected, in each country we found that HOMA-IR values were positively correlated with 183 
triglycerides (rho=0.34 in Texas-Mexico; rho=0.37 in South Africa; p <0.001) and BMI (rho=0.38 in Texas-184 
Mexico; rho=0.53 in South Africa; p <0.001; Fig S1). Because these bivariate analyses showed dispersion 185 
(an indication of error due to the contribution of other variables to HOMA-IR), we tested several models. 186 
Smoking, drugs, alcohol and contraceptives were not associated with HOMA-IR. The model with the best 187 
fit for the HOMA-IR variable required adjustment for study site, age and sex, and the interaction 188 
between BMI*triglycerides (Cohen d = 0.95, p<0.001, Fig 3A). We further visualized these adjusted 189 
relationships with 3D surface plots (Figs 3B-C). At both study sites, the simultaneous increase in BMI and 190 
triglycerides was correlated with increased adjusted HOMA-IR, but in South Africa some individuals also 191 
had high adjusted HOMA-IR despite normal triglycerides. This ANCOVA model revealed a third 192 
difference in glucose metabolism between study sites: a differential contribution of sex to adjusted 193 
HOMA-IR by study site, with higher insulin resistance in women from South Africa (mean 5.5, 95% CI 4.7, 194 
6.2) versus Texas-Mexico (mean 3.9, 95% CI 3.2, 4.7; Figure S2).  195 
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 196 
3.5 Lipid metabolism-related characteristics by study site and T2D status 197 
The contacts from both study sites differed in their lipid profiles (Table 2). The most prevalent 198 
dyslipidemias were high triglycerides and low HDL (among females) in Texas-Mexico and high LDL-c 199 
cholesterols in South Africa (p<0.05). The contacts with T2D (versus no T2D) from both study sites were 200 
more likely to have high triglycerides and total cholesterol (Table 2). Sex also had an effect on altered 201 
HDL-c, with differences between countries. Smoking, drugs, alcohol and contraceptives were not 202 
associated with lipids in either country. 203 
We expanded on the observed differences by analyzing the influence of study sites, T2D status, sex and 204 
age, on the various lipid levels. We found that triglycerides were higher in Texas-Mexico and in T2D 205 
patients (Cohen-d= 0.43-0.44; Figure 4A). Total cholesterol was higher in South Africans (Cohen-d= 0.67), 206 
but was not affected by T2D status (Figure 4B). HDL-c was lower in pre-T2D and T2D in Texas-Mexico 207 
(Cohen-d= 0.43 and 0.5; Figure 4C). Finally, LDLs had an interaction effect between study site and T2D 208 
status (Cohen-d= 0.38) (Figure 4D). In summary, lipid levels were mainly influenced by study site and 209 
T2D status. 210 
 211 
3.6 Relationship between metabolic factors underlying T2D at both study sites 212 
Our analysis of two study populations indicated variable relationships between metabolic factors that 213 
define T2D (hyperglycemia, HbA1c, HOMA-IR), obesity (BMI, waist-hip ratio) and dyslipidemias 214 
(triglycerides, total cholesterol, LDL-c and HDL-c). To further understand these relationships, we 215 
conducted a Latent Factor analysis of these variables using PCA for each study site. We found that South 216 
Africa had two components that explained 53% of variability on the seven variables, while Texas-Mexico 217 
required four components to describe the relationships between these same variables, and explained 218 
79% of total variability (Fig 5; Table S2).  219 
 220 
4. Discussion 221 
To our knowledge, this is the first study to provide an in-depth description of the 222 
sociodemographic and metabolic characteristics of adult contacts of TB patients from two distant 223 
communities with different ethnicities: The Texas-Mexico border region in North America and the 224 
Western Cape of South Africa. We report two major findings.  First, both communities revealed high 225 
prevalence rates (at least 40%) of combined pre-T2D and T2D, and at least 30% of undiagnosed T2D. 226 
These statistics provide support for evaluating the expansion of current TB contact screening protocols 227 
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to include T2D screening. Second, our analysis revealed differences in epidemiologic factors (smoking, 228 
education and contraceptive use) and metabolic status (glycated hemoglobin, insulin resistance, 229 
dyslipidemia and obesity) between the T2D patients from both ethnicities. Sex had a differential 230 
influence by study site on the metabolic status. Definition of these complex relationships is a critical step 231 
forward in understanding how these factors affect the magnitude of the contribution of T2D to the risk 232 
and adverse outcomes for TB in different ethnic groups. 233 
Previous studies have shown that the screening of TB patients for T2D is effective to detect new 234 
T2D, particularly in developing countries where T2D awareness is lower [1, 4, 22]. We now find that 235 
screening for T2D among adult TB contacts, a population at high risk for TB, can be very effective in 236 
identifying individuals with T2D. In Texas-Mexico a lack of T2D awareness was observed on both sides of 237 
the border [6/15 (40%) in Texas; 5/17 (29.4%) in Mexico]. Thus, T2D screening among contacts is not 238 
only beneficial in developing countries as suggested in a recent report from India, but also in 239 
populations with severe health disparities from developed countries.[23] The participating counties in 240 
south Texas are among the poorest counties in the US, and the enrolled TB contacts were in the lowest 241 
20% percentile of this community (data not shown) [24]. In South Africa, the proportion of new T2D 242 
among all T2D patients was even higher at 43.9%, a figure consistent with the estimated lack of T2D 243 
awareness in nearly two thirds of the adults with T2D in sub-Saharan Africa [25]. Possible explanations 244 
for the high proportion of new T2D among TB contacts is the low access to healthcare in populations at 245 
risk for TB, who generally belong to the lower socioeconomic strata [1]. This provides further support for 246 
the contribution of TB clinics as hubs for new T2D diagnosis. 247 
Our study across two continents also revealed metabolic differences in the TB contacts with 248 
T2D. South Africans had a higher proportion of high HbA1c in the presence of normal fasting blood 249 
glucose (Fig 2). Our study is not the first to report disparities in HbA1c across ethnicities [15, 26]. It has 250 
been hypothesized that higher HbA1c in Africans may result from slower erythrocyte turnover or 251 
metabolism [26, 27]. Another possibility is that elevated HbA1c in the South African cohort is due to 252 
post-prandial glucose spikes despite normal fasting glucose. This is known to vary between ethnicities 253 
[28]. To evaluate an overestimation of T2D among the South African contacts, we estimated the 254 
proportion of T2D if we would have used an HbA1C cutoff point of 6.9% as suggested previously [29] 255 
(e.g self-report of T2D, glucose ≥ 126 and/or HbA1C ≥ 6.9%). However, we found that the T2D 256 
prevalence would be 42.1% with this variation, which is similar to the 43.2% calculated in our study. 257 
Insulin resistance was associated with age and sex at both study sites. However, two findings 258 
lead us to hypothesize that insulin resistance is largely driven by the higher levels of obesity and 259 
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triglycerides in Texas-Mexico, and possibly influenced by host genetics in the leaner population from 260 
South Africa. First, insulin resistance was associated with high BMI and triglycerides at both study sites, 261 
as would be expected for T2D being driven by obesity [30]. However, in South Africa, insulin resistance 262 
was also (unexpectedly) higher among individuals with normal triglycerides regardless of BMI, 263 
suggesting a genetic component. Second, another unique feature of the South African contacts was the 264 
higher insulin resistance among females, regardless of their BMI, triglycerides or age.  265 
Lipid profiles also differed by ethnicity with elevated triglycerides more prevalent in Hispanics, 266 
and cholesterols in South African Coloureds (Table 2; Fig 4). While higher triglycerides are generally 267 
related to obesity, higher cholesterol levels are likely attributed to host genetics [31]. We speculate that 268 
high cholesterol may increase TB risk beyond the baseline already conferred by T2D. Support for this is 269 
based on reports that host cholesterol favors M. tuberculosis survival and growth, increases TB 270 
susceptibility in a mouse model, and a lower risk of TB associated with statin therapy (which lowers 271 
cholesterol)[32, 33]. The impact of triglycerides on TB risk is unclear, even though Mtb has been shown 272 
to modulate lipolysis and use fatty acids from the host cell [34].  273 
 The PCA analysis confirmed that our study sites differ in the relationships between metabolic 274 
elements associated with T2D, where some may increase TB risk (total or LDL cholesterol) and others 275 
may be protective (e.g. BMI). In South Africa, HOMA-IR and HbA1c were correlated with triglycerides, 276 
LDL-c and waist-hip ratio. These are known cardiovascular disease risk factors, particularly for T2D 277 
patients [35]. In contrast, in Hispanics, HOMA-IR and HbA1c failed to correlate with these cardiovascular 278 
risk factors (Fig 5). These differences in the underlying metabolic status may contribute to the poorly 279 
understood variability in TB risk estimates among T2D patients worldwide [4, 11]. For example, recent 280 
studies suggest that the higher death rate in TB-T2D patients is due to T2D complications, including a 281 
study in Tanzania [9, 11, 36, 37]. Thus, one would predict that TB-T2D patients with cardiovascular 282 
diseases are more likely to die. Anecdotally, our studies in Texas-Mexico have failed to detect higher risk 283 
of death among TB-T2D patients versus TB alone, even after controlling for potential confounders [38].  284 
Sociodemographic factors that increase TB risk were also distributed differently between both 285 
study site. Notably, the T2D patients from South Africa had higher smoking rates. Smoking is a risk factor 286 
for progression from latent to active TB [39], and the co-existence of T2D plus smoking has been 287 
associated with higher risk of TB or higher prevalence of MDR-TB or death during TB treatment [9, 12, 288 
40]. A greater proportion of female participants at the South African site reported hormonal 289 
contraceptive use. We have shown that medroxyprogesterone acetate decreases M. bovis BCG-induced 290 
cytokine production in MPA users [41], and increases the M. tuberculosis burden in mice [42].  291 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
11 
 
We recognize study limitations such as a relatively small sample size. Both study sites had a 292 
higher proportion of females, which reflect their higher willingness to participate in research studies. 293 
Thus, extrapolation of our findings to the entire community must be done with caution.   294 
5.  Conclusions 295 
Our findings have two major implications.  First, the high frequency of new T2D patients among 296 
adult TB contacts warrants further investigation into the expansion of routine TB contacts investigations 297 
to include T2D screening. These are likely to increase significantly the early diagnosis of T2D in 298 
economically disadvantaged populations at risk for serious T2D complications and TB development. 299 
Second, elucidation of the risk conferred by T2D towards TB development or TB treatment outcomes 300 
should be done in the context of other host sociodemographic and metabolic characteristics that may 301 
further boost or restrain M. tuberculosis survival. We posit that the combination of these variations 302 
confers differences in the “hierarchy” of TB risk and treatment outcomes, and future studies aimed at 303 
predicting TB risk among the millions of T2D patients worldwide should analyze these host variables.  304 
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Table 1.  Sociodemographic characteristics of TB contact, by study site and T2D status
a
                 
  Texas-Mexico   South Africa   
Texas-Mexico vs South 
Africa
b
 
  All   Type 2 diabetes   All   Type 2 diabetes   All No T2D T2D 
      No T2D T2D 
P 
      No T2D T2D 
P 
  
P P P 
  n=106   74 (69.8%) 32 (30.2%)   n=95   54 (56.8%) 41 (43.2%)   
Age in yrs (median, IQR) 44(13)   42.5(13) 49(16) 0.011   49(14)   45.5(13) 53(13) <0.001   0.030 0.253 0.208 
Age groups         0.082           0.107         
30 to 35 17(16%)   15(20.3%) 2(6.3%)     10(10.5%)   8(14.8%) 2(4.9%)     0.253 0.248 0.795 
36 to 59 77(72.6%)   53(71.6%) 24(75.0%)     78(82.1%)   44(81.5%) 34(82.9%)     0.110 0.197 0.407 
60 to 65 12(11.3%)   6(8.1%) 6(18.8%)     7(7.4%)   2(3.7%) 5(12.2%)     <0.001 0.310 0.434 
Sex         0.248           0.021   0.563 0.791 0.407 
Male 35(33%)   27(36.5%) 8(25.0%)     28(29.5%)   21(38.8%) 7(17.1%)           
Female 71(67%)   47(63.5%) 24(75.0%)     67(70.5%)   33(61.2%) 34(82.9%)           
Highest Education         0.830           0.859         
Elementary 12(11.8%)   8(10.8%) 4(14.3%)     10(10.5%)   6(11.1%) 4(9.8%)     0.770 0.957 0.554 
Middle 26(25.5%)   18(24.3%) 8(28.6%)     28(29.5%)   14(25.9%) 14(34.1%)     0.526 0.836 0.616 
High school 24(23.5%)   19(25.7%) 5(17.9%)     52(54.7%)   31(57.4%) 21(51.1%)     <0.001 <0.001 0.004 
College 40(39.2%)   29(39.2%) 11(39.3%)     5(5.3%)   3(5.6%) 2(4.9%)     <0.001 <0.001 <0.001 
Smoking         0.606           0.114         
Never smoked 68(64.2%)   46(62.2%) 22(68.8%)     17(20.2%)   11(23.4%) 6(16.2%)     <0.001 <0.001 <0.001 
Past smoker 15(14.2%)   10(13.5%) 5(15.6%)     6(7.1%)   1(2.1%) 5(13.5%)     <0.001 0.024 0.800 
Current smoker 23(21.7%)   18(24.3%) 5(15.6%)     61(72.6%)   35(74.5%) 26(70.3%)     <0.001 <0.001 <0.001 
Alcohol excess 7(6.6%)   5(6.8%) 2(6.3%) 0.645   4(4.2%)   2(3.7%) 2(4.9%) 0.778   0.476 0.447 0.795 
Drugs 5(4.7%)   4(5.4%) 1(3.1%) 0.522   10(10.6%)   8(14.8%) 2(4.9%) 0.134   0.118 0.071 0.701 
Contraceptive hormones 
c
 4(5.6%)   4(8.5%) 0(0%) 0.184   13(19.4%)   9(27.3%) 4(11.8%) 0.109   0.003 0.005 0.044 
Waist-Hip ratio 
d
         0.153           0.174   0.001 0.006 0.018 
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Normal  26(26.3%)   21(30.4%) 5(16.7%)     47 (49.5%)   30 (54.5%) 17(42.5%)           
At risk 73(73.7%)   48(69.6%) 25(83.3%)     48 (50.5%)   24 (44.4%) 24 (58.5%)           
BMI (median, IQR) 29.4(7.9)   29.1(8.2%) 30.1(7.2%) 0.500   26.2(10.5)   24.8(8.6%) 28.5(10.8%) 0.008   0.002 <0.001 0.421 
BMI categories         0.237           0.064         
Normal (18.5-24.9) 20(19.0%)   17(23.3%) 3(9.4%)     42(44.7%)   29(54.7%) 13(31.7%)     <0.001 <0.001 0.022 
Overweight (25-29.9) 37(35.2%)   25(34.2%) 12(37.5%)     21(22.3%)   11(20.7%) 10(24.4%)     0.044 0.095 0.226 
Obese (30+) 48(45.7%)   31(42.5%) 17(53.1%)     31(33.0%)   13(24.5%) 18(43.9%)     0.066 0.035 0.435 
a
 Data expressed as n(column %) unless specified; 
b
 p-value using two sample proportion using column percentage; 
c
 Females only; 
d
 Waist:hip ratio classified as normal (< 0.90 
in males; < 0.86 in females) or at risk if higher; Bold p values are significant or borderline significant. 
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Table 2. Lipids, insulin and insulin resistance by T2D status and study site                  
  Texas-Mexico   South Africa   Texas-Mexico vs South Africa
b
 
  
ALL    Type 2 diabetes   ALL    Type 2 diabetes   All No T2D T2D 
    No T2D T2D P       No T2D T2D P   P P P 
Lipid profiles (n, column %)
 a
                             
Triglycerides          0.003           0.008   0.065 0.077 0.083 
Normal 66(62.3%)   53(71.6%) 13(40.6%)     70(74.5%)   45(84.9%) 25(61.0%)           
High 40(37.7%)   21(28.4%) 19(59.4%)     24(25.5%)   8(15.1%) 16(39.0%)           
Total cholesterol          0.063           0.076   <0.001 0.003 0.019 
Normal 95(89.6%)   69(93.2%) 26(81.3%)     62(66.0%)   39(73.6%) 23(56.1%)           
High 11(10.4%)   5(6.8%) 6(18.8%)     32(34.0%)   14(25.9%) 18(45%)           
LDL         0.404           0.023   0.004 0.430 <0.001 
Normal  70(66%)   47(63.5%) 23(71,9%)     41(45.6%)   29(55.8%) 12(31.6%)           
High  36(34%)   27(36.5%) 9(28.1%)     49(54.4%)   23(43.4%) 26(70.3%)           
Male HDL (cut-off = 40)       0.685           0.010   <0.001 <0.001 0.641 
Normal 11(31.4%)   8(29.6%) 3(37.5%)     21(77.8%)   18(90%) 3(42.9%)           
Low 24(68.6%)   19(70.4%) 5(62.5%)     6(22.2%)   2(10%) 4(57.1%)           
Female HDL (cut-off = 50)       0.075           0.389   0.131 0.180 0.071 
Normal 28(39.4%)   22(46.8%) 6(25%)     35(52.2%)   19(57.6%) 16(47.1%)           
Low 43(60.6%)   25(53.2%) 18(75%)     32(47.8%)   14(41.2%) 18(54.5%)           
Glucose, HbA1c, insulin and HOMA-IR as estimate of insulin resistance (median, IQR)                 
Glucose (mg/dL) 104.5(35)   96.5(20) 167.5(114.5) <0.001   97.3(59.5)   86.5(19.8) 163.1(132.4) <0.001   0.072 <0.001 0.306 
HbA1c (%) 5.7(1.5)   5.5(0.4) 8.0(2.9) <0.001   6.0(2)   5.5(0.7) 7.9(3.5) <0.001   0.090 0.683 0.605 
Insulin (mU/L) 
c
 11.6 (9.2)   11.1 (8.4) 13.6 (9.4) 0.133   11.7(11.9)   9.8(8.9) 15.6(20.5) <0.001   0.960 0.077 0.194 
HOMA-IR 
c
 3.3 (3.2)   2.7 (2.0) 6.7 (4.4) <0.001   2.8 (4.7)   1.9(2.4) 5.9(5.6) <0.001   0.832 0.017 0.376 
a
 Values in mg/dL; 
b
 p-value using two sample proportion using column percentage; 
c
 Data from non-insulin users only; Bold values are significant or borderline significant 
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Figure Legends 
Fig 1. Body-mass index and waist-hip ratio in contacts by T2D status and enrollment site. A. Body-mass 
index was classified as normal, overweight or obese (see methods). B. Waist-hip ratio estimates were 
categorized into two groups: excellent plus good or average, or at risk, with cut-offs differing by sex (see 
methods). The proportion of the contacts in each category is shown by T2D status.  
Fig 2.  Criteria for diagnosis of T2D by study site. T2D diagnosis was based on the current WHO 
guidelines (see methods). The proportion of contacts fulfilling each criterium for T2D classification is 
indicated by study site. SR= self-reported only; ↑ Glu = hyperglycemia only; ↑ HbA1c = HbA1c ≥ 6.5% 
only; ↑ Glu + HbA1c = Both high glucose and HbA1c. 
Fig 3.  Relationship between adjusted HOMA-IR, BMI and triglycerides. (A) Scatter plot of correlation 
between adjusted HOMA-IR and triglycerides (mg/dL) by study site. The effect size was d=0.95 for 
triglycerides*BMI (p <0.001). Analysis was made with ANCOVA with adjustment for site, age, BMI, sex, 
triglycerides and sex*site, sex*age and BMI*triglycerides. (B and C) Surface plots of the relationships 
between between adjusted HOMA-IR, BMI and triglycerides in Texas-Mexico and South Africa. In South 
Africa there were few individuals with triglycerides below 200 mg/dl, computing unstable coefficients 
and increasing noise in these points.  
Fig 4. Dyslipidemia by study site and T2D status. Analysis of covariance contrasts lipid serum 
concentration (outcomes A-D) by T2D status (no T2D, pre-T2D and T2D) and between sites, after 
controlling for age and sex. Fisher contrast was used for T2D status as indicator variable (fixed factor), 
study site (random factor) and the model was adjusted for sex and age. A) Triglycerides were higher in 
Texas-Mexico (Cohen-d=0.43, p=0.002), and in T2D patients (Cohen-d= 0.44, p=0.003), but not pre-T2D. 
B) Total cholesterol was higher in South Africa (Cohen-d= 0.67, p=0.0001), but was not affected by T2D 
status. C) HDL-c was lower in pre-T2D (0.011) and T2D (Cohen-d= 0.43, p=0.006), in Texas-Mexico 
(Cohen-d= 0.5, p=0.001). D) LDLs had an interaction effect between study site and T2D status (Cohen-d= 
0.38, p=0.045). 
Vertical lines indicate 95% confidence intervals; Common letters indicate homogenous groups within 
T2D groups and * indicates differences by study site.  
Fig 5. Relationship between variables related to BMI and glucose and lipid metabolism in South Africa 
and Texas-Mexico. Analysis and visualization of the correlations between variables defining T2D (HbA1c, 
HOMA-IR), obesity (waist-hip ratio, BMI) and lipid metabolism (LDL-c, HDL-c, triglycerides) by PCA 
analysis.  The Kaiser-Meier-Olkin sampling adequacy was 0.627 for South Africa and 0.5 for Texas-
Mexico, and Barttlet’s test of sphericity was <0.001 for both sites.  A) In South Africa the first two 
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components (PC 1 with correlated variables HbA1c, HOMA-IR, triglycerides, LDL, and waist-hip ratio, and 
PC2 with inversely correlated variables BMI and HDL) explained 53% of the variability. B and C) The data 
from Texas-Mexico required four components (PC1 with triglycerides and HDL-c; PC2 with HOMA-IR and 
HbA1c; PC3 with waist-hip ratio and BMI; PC4 with LDL-c) to explain 79% of the total variability. Figure C 
shows the rotated component matrix of B to illustrate the separation of LDL from the other variables. 
SAfr, South Africa; TxMx, Texas-Mexico. 
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